Botulin E (Clostridium botulinum strain E3)

Botulin E (Clostridium botulinum strain E3)
Clinical data
Other namesTrenibotulinumtoxinE, TrenibotulinumtoxinE (USAN US)
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC6452H9998N1702O1973S23
Molar mass143716.28 g·mol−1

Botulin E (Clostridium botulinum strain E3) is a medication intended for the treatment for the appearance of glabellar lines.[1] Botulin E is a botulinum neurotoxin serotype E.

The most common side effects include eyelid ptosis, brow ptosis and Mephisto sign (lateral elevation of eyebrow).[1]

TrenibotulinumtoxinE is produced by the bacterium Clostridium botulinum and blocks the release of acetylcholine in the neuromuscular synapses, preventing the contraction of muscle cells.[1]

Medical uses

TrenibotulinumtoxinE is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact in adults.[1]

Society and culture

A biologics license application was submitted to the US Food and Drug Administration in April 2025.[3][4]

In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Boey, intended for the temporary improvement in the appearance of lines between the eyebrows when frowning, when these lines have an important psychological impact in adults.[1] The applicant for this medicinal product is AbbVie Limited.[1][5] trenibotulinumtoxinE was authorized for medical use in the European Union in July 2026.[1][2]

References

  1. 1 2 3 4 5 6 7 8 "Boey EPAR". European Medicines Agency (EMA). 22 May 2026. Retrieved 28 May 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. 1 2 "Boey PI". Union Register of medicinal products. 16 July 2026. Retrieved 18 July 2026.
  3. ↑ "AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines" (Press release). AbbVie. 24 April 2025. Retrieved 28 May 2026 – via PR Newswire.
  4. ↑ "AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S." (Press release). AbbVie. 23 April 2026. Retrieved 28 May 2026 – via PR Newswire.
  5. ↑ "Allergan Aesthetics Receives Positive CHMP Opinion for Boey (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults" (Press release). AbbVie. 21 May 2026. Retrieved 28 May 2026 – via PR Newswire.